Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
T-LGL
MCID: TCL002
MIFTS: 49

T-Cell Large Granular Lymphocyte Leukemia (T-LGL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for T-Cell Large Granular Lymphocyte Leukemia

About this section

MalaCards integrated aliases for T-Cell Large Granular Lymphocyte Leukemia:

Name: T-Cell Large Granular Lymphocyte Leukemia 12 52 58 15 71
Proliferation of Large Granular Lymphocytes 52 58
T-Cell Lgl Leukemia 52 58
T-Lgl 52 58
T-Cell Large Granular Lymphocyte Leukaemia 12
Large Cell Granular Lymphogenous Leukemia 52
Large Granular Lymphocytic Leukaemia 12
Leukemia, Large Granular Lymphocytic 71
Large Granular Lymphocytic Leukemia 12
Leukemia Lymphocytic Large Granular 54
T-Lgl Leukemia 52

Characteristics:

Orphanet epidemiological data:

58
t-cell large granular lymphocyte leukemia
Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare haematological diseases
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:0050751
NCIt 49 C4664
MESH via Orphanet 44 D054066
UMLS via Orphanet 72 C1955861 C2930809
Orphanet 58 ORPHA86872
UMLS 71 C1522378 C1955861
Sources

Summaries for T-Cell Large Granular Lymphocyte Leukemia

About this section
NIH Rare Diseases : 52 T-cell large granular lymphocyte leukemia is a rare cancer of a type of white blood cells called lymphocytes. T-cell large granular lymphocyte leukemia causes a slow increase in white blood cells called T lymphocytes, or T cells, which originate in the lymph system and bone marrow and help to fight infection. This disease usually affects people in their sixties. Symptoms include anemia ; low levels of platelets (thrombocytopenia ) and infection-fighting neutrophils (neutropenia ) in the blood; and an enlarged spleen . About one-third of patients are asymptomatic at the time of diagnosis. The exact cause of LGL leukemia is unknown. Doctors can diagnose this disease through a bone marrow biopsy , or by using a specialized technique in which various types of blood or bone marrow cells are separated, identified, and counted.

MalaCards based summary : T-Cell Large Granular Lymphocyte Leukemia, also known as proliferation of large granular lymphocytes, is related to large granular lymphocyte leukemia and lymphoproliferative syndrome. An important gene associated with T-Cell Large Granular Lymphocyte Leukemia is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cefepime and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A T-cell lymphocytic leukemia that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood.

Wikipedia : 74 Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an... more...

Sources

Related Diseases for T-Cell Large Granular Lymphocyte Leukemia

About this section

Diseases related to T-Cell Large Granular Lymphocyte Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 large granular lymphocyte leukemia 33.2 STAT5B STAT3 KLRD1 IL2RA CSF2
2 lymphoproliferative syndrome 31.2 STAT3 IL2RA IL2 FASLG
3 red cell aplasia 30.9 TRB STAT3 IL2RA IL2
4 pure red-cell aplasia 30.9 TRB STAT3 IL2RA IL2
5 felty syndrome 30.6 STAT3 CSF2 B3GAT1
6 virus associated hemophagocytic syndrome 30.4 IL2RB IL2
7 hairy cell leukemia 30.3 IL2RB IL2RA IL2
8 graft-versus-host disease 30.3 IL2 GZMB FASLG
9 pancytopenia 30.3 NCAM1 IL2RA CSF2 CD8A
10 myelopathy, htlv-1-associated 30.2 FASLG CNTN2
11 candidiasis 30.2 STAT3 IL2 CSF2
12 hemophagocytic lymphohistiocytosis 30.0 IL2RA IL18 GZMB
13 lymphoma, hodgkin, classic 29.9 IL2RA IL2 GZMB CSF2
14 thrombocytopenia 29.9 STAT3 IL2 IL18 GZMB FASLG CSF2
15 chronic nk-cell lymphocytosis 29.8 NCAM1 KLRD1 KIR2DL3 KIR2DL1 B3GAT1
16 juvenile rheumatoid arthritis 29.7 IL2RB IL2RA IL2 IL18
17 anaplastic large cell lymphoma 29.7 STAT3 IL2RA GZMB
18 autoimmune disease 29.7 STAT3 KLRK1 IL2RA IL2 IL18 FASLG
19 aggressive nk-cell leukemia 29.7 STAT3 NCAM1 KLRD1 GZMB FASLG B3GAT1
20 lymphadenitis 29.6 STAT3 IL2RB IL2RA IL18 FASLG
21 common variable immunodeficiency 29.6 STAT3 IL2RB IL2RA IL2 GZMB
22 aspergillosis 29.6 STAT3 IL18 CSF2
23 viral infectious disease 29.6 KLRK1 IL2RA IL2 IL18 GZMB
24 human t-cell leukemia virus type 2 29.5 CSF2 CNTN2
25 adult t-cell leukemia 29.5 STAT3 IL2RA IL2 CNTN2
26 lymphopenia 29.5 IL2RB IL2RA IL2 IL18 FASLG
27 acute leukemia 29.5 NCAM1 IL2 CSF2 CD8A
28 severe combined immunodeficiency 29.4 STAT5B IL2RB IL2RA IL2 CSF2
29 autoimmune lymphoproliferative syndrome 29.4 STAT3 IL2RA IL2 GZMB FASLG CD8A
30 peripheral t-cell lymphoma 29.4 STAT3 NCAM1 IL2RB IL2 GZMB CD8A
31 rheumatoid arthritis 29.4 IL2RB IL2RA IL2 IL18 FASLG CSF2
32 t-cell adult acute lymphocytic leukemia 29.3 IL2 CNTN2 CD8A
33 renal cell carcinoma, nonpapillary 29.3 STAT3 IL2RB IL2RA IL2 FASLG CSF2
34 leukemia, chronic myeloid 29.2 STAT5B STAT3 KLRK1 GZMB CSF2 CD8A
35 t-cell lymphoblastic leukemia/lymphoma 29.2 STAT3 IL2RB IL2RA IL2 FASLG CNTN2
36 cutaneous t cell lymphoma 29.2 TRB STAT3 IL2RB IL2RA IL2 GZMB
37 sarcoidosis 1 29.2 IL2RB IL2RA IL2 IL18 CD8A
38 myelodysplastic syndrome 29.0 STAT5B STAT3 KLRK1 IL2 GZMB FASLG
39 aplastic anemia 29.0 TRB STAT3 IL2RA IL2 IL18 FASLG
40 pneumonia 29.0 IL2 IL18 CSF2 CD8A
41 tropical spastic paraparesis 29.0 KLRK1 KIR2DL3 IL2RB IL2RA IL2 CNTN2
42 leukemia, chronic lymphocytic 29.0 STAT5B STAT3 NCAM1 KLRK1 IL2RA IL2
43 b-cell expansion with nfkb and t-cell anergy 28.9 TRB IL2RB IL2RA IL2 GZMB FASLG
44 celiac disease 1 28.6 NCAM1 MICA KLRK1 KLRD1 IL2RA IL2
45 systemic lupus erythematosus 28.5 STAT3 IL2RB IL2RA IL2 IL18 FASLG
46 lymphoma, non-hodgkin, familial 28.4 STAT3 NCAM1 IL2RB IL2RA IL2 GZMB
47 multiple sclerosis 28.4 STAT3 IL2RB IL2RA IL2 IL18 FASLG
48 leukemia, acute myeloid 28.1 STAT5B STAT3 NCAM1 KLRK1 KLRD1 KIR2DL3
49 myeloma, multiple 27.7 STAT5B STAT3 NCAM1 MICA KLRK1 IL2
50 leukemia 10.9

Graphical network of the top 20 diseases related to T-Cell Large Granular Lymphocyte Leukemia:



Diseases related to T-Cell Large Granular Lymphocyte Leukemia
Sources

Symptoms & Phenotypes for T-Cell Large Granular Lymphocyte Leukemia

About this section

GenomeRNAi Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.98 STAT5B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.98 IL18
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.98 STAT5B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.98 STAT5B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.98 KIR2DL1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.98 KIR2DL1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.98 STAT5B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.98 KIR2DL1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.98 KIR2DL1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.98 STAT5B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-3 9.98 STAT5B
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.98 IL18
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 9.98 IL18
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 9.98 IL2RB STAT5B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-5 9.98 KIR2DL1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.98 IL2RB
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.98 IL18
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.98 IL18
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.98 KIR2DL1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 9.98 KIR2DL1
21 Reduced mammosphere formation GR00396-S 9.17 FASLG IL15RA IL2RA KLRD1 KLRK1 NCAM1

MGI Mouse Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.61 CD8A CSF2 FASLG IL15RA IL2 IL2RA
2 immune system MP:0005387 9.36 CD8A CSF2 FASLG IL15RA IL18 IL2
Sources

Drugs & Therapeutics for T-Cell Large Granular Lymphocyte Leukemia

About this section

Drugs for T-Cell Large Granular Lymphocyte Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Ondansetron Approved Phase 3 99614-02-5 4595
8
Dalteparin Approved Phase 3 9005-49-6
9
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
10
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
15
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
16
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
17
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Anesthetics, Dissociative Phase 3
20 Antifungal Agents Phase 3
21 Liver Extracts Phase 3
22 Cola Phase 3
23 Analgesics Phase 3
24 Neurotransmitter Agents Phase 3
25 Analgesics, Opioid Phase 3
26 Psychotropic Drugs Phase 3
27 Anti-Anxiety Agents Phase 3
28 Antipsychotic Agents Phase 3
29 Antiprotozoal Agents Phase 3
30 Antiparasitic Agents Phase 3
31 Heparin, Low-Molecular-Weight Phase 3
32 Excitatory Amino Acid Antagonists Phase 3
33 Narcotics Phase 3
34 Hematinics Phase 3
35 Epoetin alfa Phase 3 113427-24-0
36 Anesthetics Phase 3
37 Anesthetics, General Phase 3
38 Anesthetics, Intravenous Phase 3
39 ferric gluconate Phase 3
40 Iron Supplement Phase 3
41 Amebicides Phase 3
42 Liposomal amphotericin B Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
45
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
48
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
49 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
50
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
4 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
5 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
6 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
8 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
16 Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia Completed NCT00031980 Phase 2 cyclosporine
17 A Multicenter Study to Assess the Efficacy of 506U78 in Patients With Chronic Lymphocytic Leukemia Who Are Refractory to Fludarabine and Alkylator Therapy Completed NCT00003635 Phase 2 nelarabine
18 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
19 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
20 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
22 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
23 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
24 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
25 An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases Completed NCT00002663 Phase 1, Phase 2
26 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
27 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
28 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
29 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
30 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
31 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
32 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
33 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
35 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
36 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
37 A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma Recruiting NCT03239392 Phase 1, Phase 2 BNZ132-1-40
38 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
39 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
40 Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Recruiting NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
41 Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) Active, not recruiting NCT00345345 Phase 2
42 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Active, not recruiting NCT01805037 Phase 1, Phase 2 brentuximab vedotin
43 First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL) Terminated NCT00278265 Phase 2 MTX followed by fludarabine
44 Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL) Terminated NCT01191749 Phase 2 Alemtuzumab
45 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
46 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia Terminated NCT00360776 Phase 2 tipifarnib
47 Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
48 A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia Terminated NCT00003910 Phase 2 Cyclophosphamide;Methotrexate;Prednisone
49 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2
50 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus

Search NIH Clinical Center for T-Cell Large Granular Lymphocyte Leukemia

Sources

Genetic Tests for T-Cell Large Granular Lymphocyte Leukemia

About this section
Sources

Anatomical Context for T-Cell Large Granular Lymphocyte Leukemia

About this section

MalaCards organs/tissues related to T-Cell Large Granular Lymphocyte Leukemia:

40
T Cells, Bone, Bone Marrow, Spleen, Neutrophil, Liver, Nk Cells
Sources

Publications for T-Cell Large Granular Lymphocyte Leukemia

About this section

Articles related to T-Cell Large Granular Lymphocyte Leukemia:

(show top 50) (show all 300)
# Title Authors PMID Year
1
Causes of double-negative T-cell lymphocytosis in children and adults. 61
31810993 2020
2
Hemolytic Anemia as Presentation of T-Cell Large Granular Lymphocytic Leukemia After Kidney Transplantation: A Case Report. 61
32505499 2020
3
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies. 61
32035011 2020
4
Clonal T-cell large granular lymphocyte proliferations in childhood and young adult immune dysregulation conditions. 61
32124536 2020
5
[Clinical and laboratory characteristics in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte proliferation]. 61
32447929 2020
6
High Incidence of Clonal CD8+ T-cell Proliferation in Non-malignant Conditions May Reduce the Significance of T-cell Clonality Assay for Differential Diagnosis in Oncohematology. 61
32046930 2020
7
Steady-State Design of Large-Dimensional Boolean Networks. 61
32287018 2020
8
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. 61
32348994 2020
9
Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. 61
32035354 2020
10
Retroviral sero-reactivity in LGL leukaemia patients and family members. 61
31608437 2020
11
[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia]. 61
32135626 2020
12
Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia. 61
31577464 2019
13
STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. 61
30967617 2019
14
Accelerated analysis of Boolean gene regulatory networks via reconfigurable hardware. 61
31494553 2019
15
T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. 61
31585621 2019
16
T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. 61
31250283 2019
17
Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: A case report. 61
31374037 2019
18
Identification of regulatory variables for state transition of biological networks. 61
31071365 2019
19
Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath? 61
30652530 2019
20
Scalable optimal Bayesian classification of single-cell trajectories under regulatory model uncertainty. 61
31189480 2019
21
[CD4(-)/CD8(-)/CD56(+)/TCRγδ(+) T-cell large granular lymphocyte leukemia presenting as aplastic anemia: a case report and literature review]. 61
31340629 2019
22
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. 61
30353031 2019
23
Immune dysregulation: EBV+ DLBCL and HLH in a patient with T-LGL. 61
30975643 2019
24
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization. 61
30573508 2019
25
Edgetic perturbations to eliminate fixed-point attractors in Boolean regulatory networks. 61
30823730 2019
26
[Successful treatment of pure red cell aplasia with cyclosporin in a patient with T-cell large granular lymphocytic leukemia harboring the STAT3 D661V mutation]. 61
30726823 2019
27
T-cell large granular lymphocytic (LGL) leukemia consists of CD4+/CD8dim and CD4-/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. 61
31866622 2019
28
A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. 61
30631033 2019
29
Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. 61
29963929 2019
30
[Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review]. 61
31934260 2019
31
Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. 61
29938921 2018
32
Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. 61
30455079 2018
33
Does it take three to tango? An unsuspected multimorbidity of CD8+ T cell lymphoproliferative disorder, malaria, and EBV infection. 61
30290813 2018
34
Large granular lymphocytic leukemia CD3-CD56-: a challenge for the biologist and the physician. 61
30078779 2018
35
Management of T-cell large granular lymphocyte leukemia and concurrent retroperitoneal liposarcoma. 61
30057739 2018
36
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. 61
29921385 2018
37
Mutations in the signal transducer and activator of transcription family of genes in cancer. 61
29417693 2018
38
Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia. 61
29269802 2018
39
T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group. 61
29365010 2018
40
Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging. 61
29559980 2018
41
Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. 61
29474442 2018
42
Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL). 61
29281994 2017
43
Comparison of T lymphocyte subsets in aplastic anemia and hypoplastic myelodysplastic syndromes. 61
28935248 2017
44
STAT3 mutation impacts biological and clinical features of T-LGL leukemia. 61
28977911 2017
45
Protothecosis in a patient with T cell lymphocytic leukemia. 61
28554708 2017
46
Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. 61
27715403 2017
47
Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature. 61
28427176 2017
48
Correlations in the degeneracy of structurally controllable topologies for networks. 61
28401952 2017
49
A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia. 61
27686672 2017
50
Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. 61
27755009 2017
Sources

Variations for T-Cell Large Granular Lymphocyte Leukemia

About this section
Sources

Expression for T-Cell Large Granular Lymphocyte Leukemia

About this section
Search GEO for disease gene expression data for T-Cell Large Granular Lymphocyte Leukemia.
Sources

Pathways for T-Cell Large Granular Lymphocyte Leukemia

About this section

Pathways related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.97 STAT5B STAT3 NCAM1 MICA KLRK1 KLRD1
2
ERK Signaling 63
Show member pathways
 13.81 STAT5B STAT3 IL2RB IL2RA IL2 IL18
3
PEDF Induced Signaling 63
Show member pathways
 13.67 STAT5B STAT3 IL2RB IL2RA IL2 IL18
4
Akt Signaling 63
Show member pathways
 13.42 STAT5B STAT3 IL2RB IL2RA IL2 IL18
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.37 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
6
PAK Pathway 63
Show member pathways
 13.29 IL2RB IL2RA IL2 IL18 IL15RA FASLG
7
Pathways in cancer 36
12.86 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
8
Measles 36
Show member pathways
 12.83 STAT5B STAT3 IL2RB IL2RA IL2 IL18
9
Allograft rejection 1 36
Show member pathways
 12.81 MICA KLRD1 KIR2DL3 KIR2DL1 IL2RA IL2
10
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.78 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
11
T cell receptor signaling pathway 36
Show member pathways
 12.62 TRB STAT3 IL2 IL15RA CSF2 CD8A
12
Th17 cell differentiation 36
Show member pathways
 12.61 TRB STAT5B STAT3 IL2RB IL2RA IL2
13
NF-kappaB Signaling 4
12.49 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
14
JAK-STAT signaling pathway 36
Show member pathways
 12.48 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
15
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.39 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1 IL2
16
Human T-cell leukemia virus 1 infection 36
12.38 STAT5B IL2RB IL2RA IL2 IL15RA CSF2
17
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.31 IL2RB IL2RA IL2 IL18
18
Jak Stat Signaling Pathway 66
Show member pathways
 12.16 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
19
G beta-gamma signalling through PI3Kgamma 65
Show member pathways
 12.14 IL2RB IL2RA IL2 CSF2
20
IL-2 Signaling Pathway 1
Show member pathways
 12.1 STAT5B STAT3 IL2RB IL2RA IL2
21
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
12.1 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1 CD8A
22
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.01 NCAM1 KLRK1 IL2RB IL2RA IL2 CSF2
23
IL27-mediated signaling events 1
Show member pathways
 11.96 STAT5B STAT3 IL2 IL18
24
Hematopoietic cell lineage 36
11.86 IL2RA CSF2 CD8A
25
Th17 Differentiation 64
Show member pathways
 11.82 STAT5B STAT3 GZMB
26
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.79 IL2RA IL2 FASLG CSF2
27
Dendritic Cells Developmental Lineage Pathway 64
11.78 NCAM1 IL2 CSF2 CD8A
28
Glucocorticoid receptor regulatory network 1
11.77 STAT5B IL2 CSF2
29
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.73 STAT5B IL2RB IL2RA IL2 FASLG
30
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.7 IL2RB IL2RA IL2 GZMB FASLG CD8A
31
IL12-mediated signaling events 1
Show member pathways
 11.66 TRB STAT3 IL2RB IL2RA IL2 IL18
32
Interleukin-10 signaling 65
11.54 STAT3 IL18 CSF2
33
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.51 STAT5B STAT3 IL2RA
34
Th2 Differentiation 64
11.5 IL2RB IL2RA IL2
35
IL-7 Signaling Pathway 1
Show member pathways
 11.48 STAT5B STAT3 IL2RA
36
Inflammatory Response Pathway 1
11.35 IL2RB IL2RA IL2
37
T-Cell Receptor and Co-stimulatory Signaling 1
11.31 TRB IL2 CD8A
38
IL12 signaling mediated by STAT4 1
11.3 STAT3 IL2RA IL2 IL18
39
Immune response_IL-12 signaling pathway 22
Show member pathways
 11.28 STAT5B STAT3 IL2RA
40
Cytokines and Inflammatory Response 1
11.28 TRB IL2 CSF2
41
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.26 IL2RB IL2RA IL2 IL15RA GZMB FASLG
42
Telomere Extension by Telomerase 63
Show member pathways
 11.25 STAT5B IL2RB IL2RA IL2
43
Innate Lymphoid Cells Differentiation 64
11.23 NCAM1 KLRK1 KLRD1 IL2RB IL2RA IL2
44
Development of pulmonary dendritic cells and macrophage subsets 1
10.8 STAT3 CSF2
Sources

GO Terms for T-Cell Large Granular Lymphocyte Leukemia

About this section

Cellular components related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.07 STAT3 NCAM1 MICA KLRK1 KLRD1 KIR2DL3
2 integral component of plasma membrane GO:0005887 9.87 MICA KLRK1 KIR2DL3 KIR2DL1 IL2RB FASLG
3 cell surface GO:0009986 9.56 NCAM1 MICA KLRK1 IL2RB IL2RA IL15RA
4 external side of plasma membrane GO:0009897 9.23 NCAM1 MICA KLRK1 KLRD1 IL2RB IL2RA
5 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 STAT5B STAT3 IL2 FASLG CSF2
2 MAPK cascade GO:0000165 9.91 NCAM1 IL2RB IL2RA IL2 IL18 CSF2
3 regulation of immune response GO:0050776 9.88 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1 CD8A
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 STAT3 IL2 IL18 CSF2
5 positive regulation of inflammatory response GO:0050729 9.74 STAT5B IL2 IL18
6 positive regulation of interferon-gamma production GO:0032729 9.69 KLRK1 IL2 IL18
7 positive regulation of activated T cell proliferation GO:0042104 9.67 STAT5B IL2RA IL2 IL18
8 natural killer cell activation GO:0030101 9.65 KLRK1 IL2 IL18
9 natural killer cell mediated cytotoxicity GO:0042267 9.62 MICA KLRK1 IL18 GZMB
10 immune response GO:0006955 9.61 MICA KIR2DL3 KIR2DL1 IL2RA IL2 IL18
11 regulation of regulatory T cell differentiation GO:0045589 9.6 IL2RA IL2
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.59 STAT5B STAT3
13 positive regulation of interleukin-17 production GO:0032740 9.58 IL2 IL18
14 interleukin-9-mediated signaling pathway GO:0038113 9.56 STAT5B STAT3
15 interleukin-15-mediated signaling pathway GO:0035723 9.56 STAT5B STAT3 IL2RB IL15RA
16 positive regulation of natural killer cell proliferation GO:0032819 9.55 STAT5B IL18
17 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2RA IL2
18 positive regulation of tissue remodeling GO:0034105 9.52 IL2 IL18
19 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2RA IL2
20 interleukin-2-mediated signaling pathway GO:0038110 9.46 STAT5B IL2RB IL2RA IL2
21 cytokine-mediated signaling pathway GO:0019221 9.23 STAT5B STAT3 IL2RB IL2RA IL2 IL18

Molecular functions related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 STAT5B STAT3 NCAM1 MICA KLRK1 KLRD1
2 cytokine activity GO:0005125 9.71 IL2 IL18 FASLG CSF2
3 carbohydrate binding GO:0030246 9.67 KLRK1 KLRD1 IL2 CNTN2
4 glucocorticoid receptor binding GO:0035259 9.43 STAT5B STAT3
5 MHC class I protein complex binding GO:0023024 9.26 KLRD1 CD8A
6 interleukin-2 binding GO:0019976 9.16 IL2RB IL2RA
7 interleukin-15 receptor activity GO:0042010 8.96 IL2RB IL15RA
8 interleukin-2 receptor activity GO:0004911 8.62 IL2RB IL2RA
Sources

Sources for T-Cell Large Granular Lymphocyte Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....